These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 12065780)

  • 1. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
    Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
    Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
    Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
    Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
    Kim GY; Oh YL
    Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.